Amit Sharma, MD, FASN
U.S. Vice President Cardiovascular & Renal, Medical Affairs at Bayer Pharmaceuticals
Board of directors, Kidney Health Initiative
National Kidney Foundation’s Patient Network and National Leadership Council
“Now, we have biomarkers and clinical features, that when combined with iterative machine learning, enable risk prediction formulas that give doctors the key answers needed: who is at highest risk vs not and what is the appropriate course of treatment.
This is critical, since we only have approximately 15 minutes with each patient. We need to be able to quickly review data and make an informed action plan. This risk prediction “score” will enable us to focus more resources on those who need it most and enable us to prescribe the best therapeutic.”